Mostrar el registro sencillo del ítem

dc.contributor.authorGutiérrez-Díaz, I.*
dc.contributor.authorSanz-Martinez, M.*
dc.contributor.authorCastro, A.M.*
dc.contributor.authorRodríguez-Belvís, M.V.*
dc.contributor.authorCarreira, N.*
dc.contributor.authorJiménez, S.*
dc.contributor.authorMangas, C.*
dc.contributor.authorQueralt, M.*
dc.contributor.authorHerrador, M.*
dc.contributor.authorMartín-Masot, R.*
dc.contributor.authorFerrer, P.*
dc.contributor.authorNavas-López, V.M.*
dc.contributor.authorEspín, B.*
dc.contributor.authorLeis Trabazo, María Rosaura *
dc.contributor.authorDíaz, J.J.*
dc.contributor.authorDelgado, S.*
dc.date.accessioned2025-09-12T11:46:10Z
dc.date.available2025-09-12T11:46:10Z
dc.date.issued2023
dc.identifier.citationGutiérrez-Díaz I, Sanz-Martinez M, Castro AM, Rodríguez-Belvís MV, Carreira N, Jiménez S, et al. Microbial and immune faecal determinants in infants hospitalized with COVID-19 reflect bifidobacterial dysbiosis and immature intestinal immunity. European Journal of Pediatrics. 2023;182(10):4633-45.
dc.identifier.issn1432-1076
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/64e2a68a4a4f093d56e74a8f
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21785
dc.description.abstractThe coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide, seriously endangering human health. Although SARS-CoV-2 had a lower impact on paediatric population, children with COVID-19 have been reported as suffering from gastrointestinal (GI) symptoms at a higher rate than adults. The aim of this work was to evaluate faeces as a source of potential biomarkers of severity in the paediatric population, with an emphasis on intestinal microbiota and faecal immune mediators, trying to identify possible dysbiosis and immune intestinal dysfunction associated with the risk of hospitalization. This study involved 19 patients with COVID-19 under 24 months of age hospitalized during the pandemic at 6 different hospitals in Spain, and it included a comparable age-matched healthy control group (n = 18). Patients and controls were stratified according to their age in two groups: newborns or young infants (from 0 to 3 months old) and toddlers (infants from 6 to 24 months old). To characterize microbial intestinal communities, sequencing with Illumina technology of total 16S rDNA amplicons and internal transcribed spacer (ITS) amplicons of bifidobacteria were used. Faecal calprotectin (FC) and a range of human cytokines, chemokines, and growth factors were measured in faecal samples using ELISA and a multiplex system. Significant reduction in the abundance of sequences belonging to the phylum Actinobacteria was found in those infants with COVID-19, as well as in the Bifidobacteriaceae family. A different pattern of bifidobacteria was observed in patients, mainly represented by lower percentages of Bifidobacterium breve, as compared with controls. In the group of hospitalized young infants, FC was almost absent compared to age-matched healthy controls. A lower prevalence in faecal excretion of immune factors in these infected patients was also observed. Conclusion: Hospitalized infants with COVID-19 were depleted in some gut bacteria, such as bifidobacteria, in particular Bifidobacterium breve, which is crucial for the proper establishment of a functional intestinal microbiota, and important for the development of a competent immune system. Our results point to a possible immature immune system at intestine level in young infants infected by SARS-CoV2 requiring hospitalization. What is Known: - Although SARS-CoV-2 had a lower impact on paediatric population, children with COVID-19 have been reported as suffering from gastrointestinal symptoms at a higher rate than adults. - Changes in microbial composition have been described in COVID-19 adult patients, although studies in children are limited. What is New: - The first evidence that hospitalized infants with COVID-19 during the pandemic had a depletion in bifidobacteria, particularly in Bifidobacterium breve, beneficial gut bacteria in infancy that are crucial for the proper establishment of a competent immune system. - In young infants (under 3 months of age) hospitalized with SARS-CoV2 infection, the aberrant bifidobacterial profile appears to overlap with a poor intestinal immune development as seen by calprotectin and the trend of immunological factors excreted in faeces.
dc.description.sponsorshipOpen Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This word was funded in part by a CSIC (Consejo Superior de Investigaciones Cientificas) internal project PIE reference 202070E237. The research was also funded by the European Commission-Next Generation EU (REGULATION EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global). I. G-D. has a grant FJC2021-047052-I financed by MCIN/AEI/10.13039/501100011033 and by European Union NextGenera-tionEU/PRTR. Grant AYUDA-20201-50910 from the Government of Asturias Principality (FICYT, supported by FEDER) is also received.
dc.languageeng
dc.rightsAttribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdult *
dc.subject.meshInfant *
dc.subject.meshInfant, Newborn *
dc.subject.meshHumans *
dc.subject.meshChild, Preschool *
dc.subject.meshBifidobacterium *
dc.subject.meshCOVID-19 *
dc.subject.meshDysbiosis *
dc.subject.meshRNA, Viral *
dc.subject.meshSARS-CoV-2 *
dc.subject.meshFeces *
dc.subject.meshLeukocyte L1 Antigen Complex *
dc.titleMicrobial and immune faecal determinants in infants hospitalized with COVID-19 reflect bifidobacterial dysbiosis and immature intestinal immunity
dc.typeArtigo
dc.authorsophosGutiérrez-Díaz, I.; Sanz-Martinez, M.; Castro, A.M.; Rodríguez-Belvís, M.V.; Carreira, N.; Jiménez, S.; Mangas, C.; Queralt, M.; Herrador, M.; Martín-Masot, R.; Ferrer, P.; Navas-López, V.M.; Espín, B.; Leis, R.; Díaz, J.J.; Delgado, S.
dc.identifier.doi10.1007/s00431-023-05140-8
dc.identifier.sophos64e2a68a4a4f093d56e74a8f
dc.issue.number10
dc.journal.titleEuropean Journal of Pediatrics*
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Pediatría
dc.page.initial4633
dc.page.final4645
dc.relation.projectIDCRUE-CSIC agreement
dc.relation.projectIDSpringer Nature
dc.relation.projectIDCSIC (Consejo Superior de Investigaciones Cientificas) [202070E237]
dc.relation.projectIDEuropean Commission-Next Generation EU (REGULATION EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global)
dc.relation.projectIDMCIN/AEI [FJC2021-047052-I]
dc.relation.projectIDEuropean Union NextGenera-tionEU/PRTR
dc.relation.projectIDFEDER [AYUDA-20201-50910]
dc.relation.publisherversionhttps://doi.org/10.1007/s00431-023-05140-8
dc.rights.accessRightsopenAccess*
dc.subject.keywordAS Santiago
dc.subject.keywordCHUS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number182


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 International (CC BY 4.0)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International (CC BY 4.0)